Analysts expect Spark Therapeutics Inc (NASDAQ:ONCE) to announce earnings per share of ($0.45) for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Spark Therapeutics’ earnings. The highest EPS estimate is $1.41 and the lowest is ($1.71). Spark Therapeutics posted earnings per share of ($1.70) in the same quarter last year, which would suggest a positive year-over-year growth rate of 73.5%. The business is expected to issue its next quarterly earnings report on Tuesday, May 8th.
On average, analysts expect that Spark Therapeutics will report full-year earnings of ($3.68) per share for the current year, with EPS estimates ranging from ($6.24) to ($1.44). For the next year, analysts forecast that the business will post earnings of ($4.32) per share, with EPS estimates ranging from ($6.09) to ($2.60). Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Spark Therapeutics.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, February 20th. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.73). The firm had revenue of $7.41 million for the quarter, compared to analysts’ expectations of $9.53 million. Spark Therapeutics had a negative net margin of 2,100.80% and a negative return on equity of 59.38%.
A number of analysts recently weighed in on ONCE shares. BMO Capital Markets reissued a “buy” rating and issued a $101.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, November 15th. Credit Suisse Group started coverage on shares of Spark Therapeutics in a research report on Wednesday, January 17th. They issued an “outperform” rating and a $61.00 price objective on the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $105.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, January 24th. Barclays reissued a “buy” rating and issued a $54.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, December 13th. Finally, Goldman Sachs Group lowered shares of Spark Therapeutics from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $106.00 to $58.00 in a research report on Thursday, December 14th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, five have given a hold rating and sixteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $70.58.
Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its stake in Spark Therapeutics by 15.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after acquiring an additional 241,016 shares in the last quarter. Ameriprise Financial Inc. grew its stake in Spark Therapeutics by 6.0% in the 3rd quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after acquiring an additional 11,785 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in Spark Therapeutics in the 3rd quarter worth about $5,286,000. Alyeska Investment Group L.P. bought a new position in Spark Therapeutics in the 3rd quarter worth about $13,519,000. Finally, Principal Financial Group Inc. grew its stake in Spark Therapeutics by 23.8% in the 3rd quarter. Principal Financial Group Inc. now owns 54,088 shares of the biotechnology company’s stock worth $4,822,000 after acquiring an additional 10,399 shares in the last quarter.
Shares of Spark Therapeutics (NASDAQ:ONCE) opened at $61.58 on Friday. The stock has a market cap of $2,291.85, a PE ratio of -7.97 and a beta of 2.82. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $91.75.
COPYRIGHT VIOLATION WARNING: “-$0.45 Earnings Per Share Expected for Spark Therapeutics Inc (ONCE) This Quarter” was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://ledgergazette.com/2018/03/19/0-45-earnings-per-share-expected-for-spark-therapeutics-inc-once-this-quarter.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.